0
Es befinden sich keine Waren im Warenkorb !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Start > Glycoprotein E (VZV)

Glycoprotein E (VZV)

Brief Information

Name:Envelope (E) protein
Target Synonym:gE-1,Envelope glycoprotein E,gE
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:2
Lastest Research Phase:Phase 1 Clinical

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

VZV-M544-SPR
 Glycoprotein E (VZV) SPR

Anti-Glycoprotein E (VZV) Antibody, Human IgG1 (1B10) (Cat. No. VZV-M544) captured on Protein A Chip can bind Varicella zoster virus (strain Oka vaccine) Envelope Glycoprotein E (gE), His Tag (Cat. No. GLE-V52H3) with an affinity constant of 5.63 nM as determined in SPR assay (Biacore 8K) (Routinely tested).

VZV-M545-SPR
 Glycoprotein E (VZV) SPR

Anti-Glycoprotein E (VZV) Antibody, Human IgG1 (4G2) (Cat. No. VZV-M545) captured on Protein A Chip can bind Varicella zoster virus (strain Oka vaccine) Envelope Glycoprotein E (gE), His Tag (Cat. No. GLE-V52H3) with an affinity constant of 4.81 nM as determined in SPR assay (Biacore 8K) (Routinely tested).

Glycoprotein E (VZV) 分子别名

gE

Glycoprotein E (VZV) 分子背景

Varicella-zoster virus (VZV) is a neurotropic virus belonging to the Herpesviridae family. Primary VZV infection causes chickenpox and is followed by a life-long latent infection established mainly in the cranial and dorsal root ganglia. Reactivation of the virus is often associated with shingles (herpes zoster). Glycoprotein E (gE) is one of the known glycoproteins (gB, gC, gE, gH, gI, gK, gI) of VZV that is most abundantly expressed on the surface of virus and infected cells, playing an important role in viral replication and cell-to-cell spread. The strongly immunogenic gE can provide strong IgG signal in body fluid, which makes it ideal to be developed as an antigen for analysis of IgG antibodies. gE also demonstrates high potency as a vaccine immunogen and is formulated as the single viral envelope protein that constitutes the GSK VZV recombinant subunit vaccine Shingrix®.

Glycoprotein E (VZV) 前沿进展

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
SAR-440894 SAR-440894 Phase 1 Clinical National Institute Of Allergy And Infectious Diseases (Niaid) Chikungunya Fever Details
LHF-535 LHF-535; LHF-535-SDD Phase 1 Clinical Kineta Inc Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
Lichtstrasse 35,4056 Basel, Switzerland

Nachricht schicken